Show simple item record

dc.contributor.authorHuang, Zhenzhen
dc.contributor.authorLin, Lin
dc.contributor.authorGao, Yao
dc.contributor.authorChen, Yongjing
dc.contributor.authorYan, Xiaomei
dc.contributor.author颜晓梅
dc.contributor.authorXing, Jinchun(Xiamen First Hosp, Dept Urol)
dc.contributor.authorHang, Wei
dc.contributor.author杭纬
dc.date.accessioned2012-02-25T04:58:58Z
dc.date.available2012-02-25T04:58:58Z
dc.date.issued2011-07-28
dc.identifier.citationMOLECULAR & CELLULAR PROTEOMICS,2011,10(10):zh_CN
dc.identifier.issn1535-9476
dc.identifier.urihttp://dx.doi.org/doi:10.1074/mcp.M111.007922
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/11505
dc.identifier.uriWOS:000295773800021
dc.description.abstractThe purpose of this study was to use metabonomic profiling to identify a potential specific biomarker pattern in urine as a noninvasive bladder cancer (BC) detection strategy. A liquid chromatography-mass spectrometry based method, which utilized both reversed phase liquid chromatography and hydrophilic interaction chromatography separations, was performed, followed by multivariate data analysis to discriminate the global urine profiles of 27 BC patients and 32 healthy controls. Data from both columns were combined, and this combination proved to be effective and reliable for partial least squares-discriminant analysis. Following a critical selection criterion, several metabolites showing significant differences in expression levels were detected. Receiver operating characteristic analysis was used for the evaluation of potential biomarkers. Carnitine C9:1 and component I, were combined as a biomarker pattern, with a sensitivity and specificity up to 92.6% and 96.9%, respectively, for all patients and 90.5% and 96.9%, respectively for low-grade BC patients. Metabolic pathways of component I and carnitine C9: 1 are discussed. These results indicate that metabonomics is a practicable tool for BC diagnosis given its high efficacy and economization. The combined biomarker pattern showed better performance than single metabolite in discriminating bladder cancer patients, especially low-grade BC patients, from healthy controls. Molecular & Cellular Proteomics 10: 10.1074/mcp.M111.007922, 1-10, 2011.zh_CN
dc.description.sponsorshipXiamen University; Department of Science and Technology of Fujian Province[2009D023]; Medical Center Construction Foundation of Xiamenzh_CN
dc.language.isoenzh_CN
dc.publisherAMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INCzh_CN
dc.titleBladder Cancer Determination Via Two Urinary Metabolites: A Biomarker Pattern Approachzh_CN
dc.typeArticlezh_CN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record